Novast

Novast, founded in 2005 by Dr. Zhang Guohua and his technical team in Jiangsu, develops, produces, and supplies prescription drugs with proprietary intellectual property for global markets.

Nantong Novast Laboratories has priced its IPO to raise approximately **$140 million** in its initial public offering. The pharmaceutical company finalized the terms in **September 2026**, aiming to secure capital through the public markets. The deal reflects a strategic move to expand operations or fund research initiatives.

Sep 2026DealroomNews article

Shandong Buchang Pharmaceuticals terminates its development, supply, and marketing agreement with NOVAST Laboratories. The move follows shifts in the market environment and changes in the company’s operational status. The agreement covered collaborative efforts in pharmaceutical development and distribution.

Dec 2024Fineline Info & TechNews article

Eli Lilly and Novast are investing up to **$70 million** to expand drug manufacturing in China. The project builds on a **two-year-old partnership** to produce Lilly-branded generic medications. The companies aim to strengthen local production capacity for affordable pharmaceuticals.

Mar 2014GENNews article

Eli Lilly and Novast Pharmaceuticals have broken ground on a new state-of-the-art manufacturing facility in Nantong, China. The expansion aims to bolster production capacity for pharmaceuticals, supporting regional and global demand. The facility will integrate advanced technologies for efficient drug manufacturing processes.

Mar 2014Fierce PharmaNews article